Tau's Mitochondrial Damage: What Stanford Found Before Tangles Form
Tau damages neuronal mitochondria years before neurofibrillary tangles form, making early-stage tau pathology a primary driver rather than a downstream effect of Alzheimer's disease.
Pre-tangle tau directly disrupts mitochondrial protein import, membrane potential, and electron transport chain function, flooding neurons with reactive oxygen species through a self-amplifying cycle.
Mitochondrial fragmentation by early tau pathology cuts off energy supply to synapses, providing a mechanistic explanation for why synaptic loss and cognitive decline precede significant neuronal death.
Plasma phospho-tau 217 is emerging as a blood-based biomarker capable of detecting pre-symptomatic tau-driven neuronal stress with area-under-the-curve values exceeding 0.95 in cohort studies.
Mitochondrial support strategies, including aerobic exercise, methylene blue, and mitophagy enhancement, target the same mechanistic pathway that the Stanford research identifies as the earliest site of injury.
The conditions that accelerate tau-driven mitochondrial damage in neurons, including insulin resistance, chronic inflammation, and sleep disruption, are the same targets of systemic longevity medicine.
Anti-amyloid therapies failing to halt progression despite plaque clearance is now mechanistically explicable: once tau-driven mitochondrial damage begins, it sustains itself independently of amyloid stimulation.
For decades, the prevailing story of Alzheimer's disease ran in a predictable sequence: amyloid plaques accumulate outside neurons, tau protein misfolds and forms tangles inside them, neurons die, and cognition crumbles. That sequence gave the field its dominant therapeutic targets and, repeatedly, its most expensive clinical failures. A landmark study from Stanford University has begun to rewrite that sequence in a way that changes not just the biology of Alzheimer's but the entire logic of when and how to intervene. The finding is this: tau inflicts catastrophic damage on neuronal mitochondria long before it ever forms the neurofibrillary tangles that have historically defined its pathology. Tau's mitochondrial damage in neurons, it turns out, is not a late-stage consequence of disease. It is an early driver of it.
The implications are significant for anyone thinking about brain health across a lifespan. If mitochondrial dysfunction in neurons precedes tangle formation by potentially years or decades, then waiting for cognitive symptoms before acting is not a strategy. It is a forfeit. This research repositions the mitochondrion, the organelle responsible for producing the ATP that powers every synaptic signal and every act of memory consolidation, from a downstream casualty of tau pathology to a proximal target of tau toxicity. Understanding exactly how tau accomplishes this, and what can be done about it, is now one of the more urgent questions in neuroscience and longevity medicine.
The Protein That Was Supposed to Stabilize
Tau is not, in its healthy form, a villainous molecule. It is a microtubule-associated protein whose primary job is structural: tau binds to microtubules, the rigid internal scaffolding of neurons, and stabilizes them. Think of microtubules as the railroad tracks along which neurons transport nutrients, organelles, and molecular cargo from the cell body out to the distant tips of axons. Tau is the tie-plate that holds those tracks in alignment. Without functional tau, the tracks buckle. With too much tau, or with tau that has been abnormally modified, the dynamics of that system break down in ways that extend far beyond mere structural instability.
In Alzheimer's disease and a broader class of conditions called tauopathies, tau becomes hyperphosphorylated. Phosphorylation is the attachment of phosphate groups to specific sites on a protein, a modification that normally acts as a molecular on/off switch. When tau is hyperphosphorylated, it detaches from microtubules, loses its stabilizing function, and begins to aggregate. The classical endpoint of this process is the neurofibrillary tangle, a dense intracellular knot of tau filaments that has been visible in post-mortem brain tissue since Alois Alzheimer first described it in 1907 [1]. For most of the twentieth century, the tangle was considered the primary mechanism of tau-related neuronal death.
What the Stanford work challenged was the assumption that everything harmful about tau happens inside those tangles. The research, led by investigators at Stanford's Wu Tsai Neurosciences Institute, demonstrated that soluble, pre-tangle forms of tau, the kind circulating within neurons before any visible aggregation occurs, directly impair mitochondrial function through mechanisms that are specific, measurable, and mechanistically distinct from the structural collapse caused by tangle formation [2]. The neuron is being poisoned before the visible evidence of disease even appears.
How Tau Reaches the Mitochondria
The mitochondrion is not simply a power plant sitting passively inside the cell. In neurons especially, mitochondria are dynamic organelles that must travel long distances, fuse and divide in response to metabolic demand, and be selectively eliminated when damaged, a process called mitophagy. All of these functions require the same microtubule-based transport infrastructure that tau is supposed to maintain. This creates an immediate and logical point of vulnerability: when tau becomes hyperphosphorylated and detaches from microtubules, it does not simply float harmlessly in the cytoplasm. It accumulates in regions of the cell where it can directly interact with mitochondria.
The Stanford team used a combination of advanced microscopy, proteomics, and iPSC-derived human neurons, neurons grown from reprogrammed human stem cells, to map exactly what early-stage tau does to mitochondria at the molecular level [2]. The findings revealed that hyperphosphorylated tau associates directly with mitochondrial membranes, particularly the outer mitochondrial membrane, where it disrupts the protein import machinery. Mitochondria, unlike most organelles, manufacture only a small fraction of their own proteins. The vast majority, roughly 99 percent, are encoded by nuclear DNA, synthesized in the cytoplasm, and then imported through specialized protein channels in the outer membrane called translocases [3]. Tau's interference with this import machinery is essentially equivalent to blockading the loading dock of a factory. Raw materials pile up outside. The assembly lines inside grind to a halt.
Beyond disrupting protein import, the Stanford data showed that early tau pathology impairs mitochondrial membrane potential, the electrochemical gradient across the inner mitochondrial membrane that drives ATP synthesis. This gradient functions like the pressure differential in a hydroelectric turbine: when it collapses, the turbine stops generating power. In neurons, which cannot rely on glycolysis alone to meet their extraordinary energy demands, a drop in ATP production is not an inconvenience. It is an existential threat to synaptic function and cell survival.
Fragmenting the Network Before the Tangles Arrive
Healthy mitochondria in neurons do not exist as isolated, bean-shaped organelles. They form interconnected networks that constantly fuse and divide, a process regulated by proteins including dynamin-related protein 1, known as DRP1, and mitofusins. This fusion-fission balance is exquisitely sensitive to cellular stress. When a mitochondrion is damaged, the network isolates it through fission, fragmenting it into a smaller unit that can be tagged for mitophagy and removed. The system works like a quality-control conveyor belt: damage is detected, isolated, and cleared before it can contaminate healthy mitochondria.
The Stanford study found that pre-tangle tau disrupts this balance systematically, shifting mitochondrial dynamics toward excessive fission [2]. The result is a fragmented mitochondrial network that cannot sustain the long-range transport neurons depend on. Axons that extend centimeters or even meters from the cell body, structures containing thousands of synapses, begin to run out of local energy supply. This energy deficit at the synapse maps directly onto the earliest observable deficits in Alzheimer's disease: the impairment of synaptic plasticity and the disruption of memory consolidation that precedes any structural neuronal loss by years [4].
The mitochondrial fragmentation picture is reinforced by independent research showing that DRP1 is activated in Alzheimer's brain tissue at Braak stages as low as I and II, the earliest pathological classifications, long before widespread neuronal death is observed [5]. The convergence of these findings suggests that the fragmentation is not incidental but mechanistically central to early disease progression.
Tau's mitochondrial toxicity in neurons appears to precede tangle formation by years, repositioning mitochondrial dysfunction from a downstream consequence of Alzheimer's disease to a proximal driver of it.
The Electron Transport Chain Under Siege
Inside every mitochondrion, the inner membrane is densely packed with protein complexes that form the electron transport chain, a series of molecular machines that pass electrons from one to the next like a relay, using the released energy to pump protons across the membrane and ultimately synthesize ATP. This chain has five major complexes, numbered I through V, each performing a specific step in the process. The integrity of this chain is so fundamental to cell survival that it is monitored constantly by mitochondrial quality-control systems.
What the Stanford research and complementary work from other groups have established is that early tau pathology impairs Complex I activity in particular [2, 6]. Complex I, also known as NADH:ubiquinone oxidoreductase, is the largest of the five complexes and the primary entry point for electrons derived from NADH. It is also one of the main sites of superoxide production when the chain is impaired, superoxide being the reactive oxygen species that can oxidize lipids, proteins, and DNA with indiscriminate destructive force. When early tau pathology compromises Complex I, the chain does not simply slow down. It begins to leak electrons that react with oxygen to form superoxide, flooding the neuron with oxidative stress.
This creates a vicious cycle. Oxidative stress further promotes tau hyperphosphorylation through the activation of multiple kinases, including glycogen synthase kinase-3 beta (GSK-3β) and cyclin-dependent kinase 5 (CDK5) [7]. More hyperphosphorylated tau produces more mitochondrial dysfunction. More mitochondrial dysfunction produces more oxidative stress. More oxidative stress drives more tau phosphorylation. The cycle, once initiated, accelerates independently of whatever upstream event triggered it in the first place. This is why interventions aimed solely at tau aggregation, the tangles themselves, have consistently failed to halt progression in clinical trials: the cycle continues even when tangle formation is blocked.
Mitophagy: The Clearance System That Fails
The body's first line of defense against damaged mitochondria is mitophagy, the selective autophagy of dysfunctional mitochondria. When a mitochondrion's membrane potential collapses, two proteins, PINK1 and Parkin, work in concert to tag the damaged organelle with ubiquitin chains, flagging it for engulfment by an autophagosome and delivery to the lysosome for degradation. The system is elegant and efficient under normal conditions. Under the conditions created by early tau pathology, it is overwhelmed.
Research published in the Journal of Neuroscience has shown that hyperphosphorylated tau impairs the PINK1-Parkin pathway directly, reducing the efficiency of mitochondrial tagging and slowing autophagosome recruitment [8]. The result is an accumulation of damaged, membrane-potential-deficient mitochondria that cannot be cleared. These dysfunctional organelles continue to generate reactive oxygen species while failing to produce adequate ATP, compounding the energy deficit and the oxidative burden simultaneously. The loading dock is not just blockaded; the disposal system for broken machinery has also seized up.
The connection to neurodegeneration extends beyond Alzheimer's. In Parkinson's disease, loss-of-function mutations in PINK1 and Parkin are among the most well-characterized genetic causes of familial disease, underscoring how central mitophagy failure is to neuronal survival across different tauopathies and synucleinopathies [9]. The mitochondrial quality-control system is not specific to Alzheimer's. It is a universal requirement for neuronal longevity, and tau appears capable of compromising it before the first tangle ever forms.
Reading the Signal: Tau, Mitochondria, and the Cerebrospinal Fluid
One of the most practically significant aspects of the Stanford finding is what it implies for biomarker detection. If tau-driven mitochondrial damage precedes tangle formation, then biomarkers of that damage should theoretically appear earlier in the disease timeline than phospho-tau or amyloid measures currently used in clinical diagnostics. Several candidate biomarkers are now under active investigation.
Cerebrospinal fluid (CSF) levels of mitochondrial proteins, particularly components of the electron transport chain complexes that leak into the CSF when neurons are damaged, have shown promise as early indicators of neuronal metabolic stress [10]. Plasma levels of phospho-tau 217, a specific phosphorylation site on tau that appears to reflect early synaptic and mitochondrial stress rather than tangle burden, have shown remarkable accuracy for detecting pre-symptomatic Alzheimer's pathology in large cohort studies, with area-under-the-curve values exceeding 0.95 in some analyses [11]. The specificity of phospho-tau 217 as a blood-based biomarker is now recognized as sufficient for population-level screening in guidelines under development by several national neurology societies.
Beyond CSF and blood markers, PET imaging using mitochondria-targeted tracers is an emerging approach to directly visualize neuronal metabolic activity in living brains. FDG-PET, which measures glucose uptake as a proxy for mitochondrial ATP production, has long been used in Alzheimer's research and reliably shows hypometabolism in the entorhinal cortex and posterior cingulate years before amyloid PET positivity [12]. The Stanford work provides a mechanistic explanation for that early hypometabolism: it reflects tau-driven mitochondrial dysfunction, not simply neuronal loss.
The Synaptic Consequence: Where Cognition Meets Energy
No neuron embodies the energy demands of cognition more acutely than the glutamatergic pyramidal cell in the hippocampus and prefrontal cortex. These cells fire repeatedly during the encoding of new memories, requiring rapid and sustained ATP production at synapses that may be located more than a millimeter from the cell body. A mitochondrial network fragmented by early tau pathology cannot reliably deliver energy to these distal synapses. The consequence is a failure of long-term potentiation, the synaptic strengthening mechanism that underlies memory formation.
Studies in tau transgenic mouse models, including the well-characterized rTg4510 line that overexpresses a mutant human tau, show synaptic loss and long-term potentiation deficits that precede tangle formation by weeks and correlate specifically with mitochondrial fragmentation in dendritic spines [13]. Dendritic spines are the small protrusions on a neuron's receiving branches where most synaptic connections form, structures so energetically demanding that they each contain at least one dedicated mitochondrion. When tau fragments the mitochondrial network, those spine-resident mitochondria are among the first to fail.
Synaptic loss in Alzheimer's disease is the strongest pathological correlate of cognitive decline, and the Stanford data suggests that mitochondrial fragmentation by pre-tangle tau is a primary mechanism driving that loss.
This mechanistic link between tau, mitochondrial fragmentation, and synaptic failure also explains why cognitive reserve, the brain's capacity to function normally despite accumulating pathology, is not unlimited. High cognitive reserve, built through education, social engagement, and physical activity, may sustain synaptic function longer in the face of early tau-driven mitochondrial stress. But it cannot compensate indefinitely once the energy supply to synapses falls below a functional threshold. The reserve buys time. It does not eliminate the deficit.
Intervention Targets: What the Mechanism Suggests
Understanding tau's mitochondrial toxicity as an early event rather than a late one reframes the question of neuroprotective intervention. The goal shifts from dissolving tangles that have already formed to preventing the upstream mitochondrial damage that predicts cognitive decline. Several intervention points emerge from the mechanistic picture.
The first is mitochondrial membrane potential preservation. Compounds that support electron transport chain efficiency and reduce superoxide leakage at Complex I are directly relevant to the pathological sequence described by the Stanford work. Methylene Blue, a small molecule with decades of research history in neurological applications, acts as an alternative electron carrier capable of bypassing Complex I and II dysfunction, shunting electrons directly to cytochrome c and maintaining mitochondrial membrane potential under conditions of electron transport chain impairment [14]. Clinical studies in mild-to-moderate Alzheimer's disease have shown that methylthioninium, the active form of methylene blue, can slow cognitive decline on validated scales, with the most robust effects observed in patients with early-stage disease, precisely the window in which tau-driven mitochondrial damage predominates over tangle burden [15].
The second intervention target is mitophagy enhancement. Clearing damaged mitochondria before they amplify the vicious cycle of tau phosphorylation and oxidative stress is a logical priority. Urolithin A, a gut metabolite produced from ellagitannins found in pomegranates and berries, has emerged as one of the most studied mitophagy activators in human clinical trials. A randomized controlled trial published in Nature Aging demonstrated that oral urolithin A supplementation significantly increased mitophagy markers in human skeletal muscle and improved mitochondrial gene expression profiles compared to placebo [16]. While the primary clinical data for urolithin A are in muscle, the mechanistic rationale for neuronal mitophagy enhancement is supported by preclinical evidence showing PINK1-Parkin pathway activation in neuronal cultures [17].
The third target is tau hyperphosphorylation itself, specifically the kinases that drive it. GSK-3β inhibition has been a major drug-discovery focus, with lithium, a GSK-3β inhibitor with decades of clinical use in psychiatry, showing reductions in CSF phospho-tau in a randomized pilot trial in Alzheimer's patients [18]. Metformin, the biguanide used widely in metabolic medicine, activates AMPK, which in turn inhibits GSK-3β and has shown tau-lowering effects in preclinical tauopathy models [19]. Metformin's relevance to neurodegeneration risk is an active area of investigation, with large epidemiological studies suggesting reduced dementia incidence in long-term users, though prospective randomized trial data in non-diabetic populations are still accumulating.
Exercise represents the most evidence-dense intervention for the full mechanistic pathway under consideration. Aerobic exercise increases brain-derived neurotrophic factor (BDNF), stimulates mitochondrial biogenesis through PGC-1α activation, enhances mitophagy flux, and reduces tau phosphorylation in preclinical models [20]. A systematic review of randomized controlled trials found that moderate-intensity aerobic exercise improves hippocampal volume and cognitive performance in older adults at risk for Alzheimer's, with effect sizes that meaningfully exceed those seen in pharmacological trials of amyloid-targeting agents [21]. The mechanism is not singular, but mitochondrial support, specifically preserving the energy supply to synapses that tau pathology threatens to cut off, appears to be a central component of that neuroprotective effect.
For individuals seeking a structured framework for monitoring and acting on these risks, programs like Longevity Optimization that integrate biomarker tracking with personalized protocol design represent a clinically meaningful approach. The ability to track phospho-tau 217 in blood, assess mitochondrial function through metabolic testing, and implement tailored interventions before symptoms emerge is precisely the kind of proactive architecture that the Stanford finding argues for.
The Broader Tauopathy Landscape
Alzheimer's disease accounts for roughly 60 to 70 percent of dementia cases globally, but it is far from the only condition in which tau pathology drives neurodegeneration. Frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and chronic traumatic encephalopathy, the condition found in contact sport athletes with repeated head injuries, are all primary tauopathies in which tau pathology occurs without the amyloid plaques characteristic of Alzheimer's [22]. The Stanford finding that tau inflicts mitochondrial damage through mechanisms independent of tangle formation has implications for all of these conditions, not only for Alzheimer's.
In chronic traumatic encephalopathy, the relevance is particularly stark. Tau pathology in CTE begins in highly specific locations, the depths of cortical sulci around small blood vessels, and spreads outward from there in a pattern distinct from Alzheimer's disease [23]. In athletes with documented CTE, mitochondrial dysfunction in neurons surrounding tau-positive regions has been observed at autopsy, consistent with the idea that early-stage, soluble tau is exerting mitochondrial toxicity in advance of tangle formation [24]. The Stanford mechanism is not disease-specific. It is tau-specific. And tau, once misfolded, appears to target the mitochondrial machinery of neurons with a precision that the tangle-centric view of tauopathy entirely misses.
What Remains Unknown
Intellectual honesty requires acknowledging what this research cannot yet establish. The Stanford study, like all iPSC-based and animal model work, faces the fundamental translational challenge of moving from cellular and transgenic systems to the complexity of a living human brain. iPSC-derived neurons, while powerful, do not fully replicate the network-level interactions of neurons embedded in a brain, and tau transgenic models often overexpress mutant tau at levels that may not reflect the gradual accumulation seen in sporadic Alzheimer's disease.
The question of causality also deserves careful handling. The finding that pre-tangle tau impairs mitochondrial function does not by itself establish that this mitochondrial damage is the primary driver of cognitive decline in human disease. It could be a major contributor to a multicausal process in which amyloid, neuroinflammation, vascular dysfunction, and metabolic dysregulation all interact. The honest position is that tau-driven mitochondrial damage in neurons is now a mechanistically established and temporally early component of tauopathy, not necessarily the singular cause of Alzheimer's disease.
What is also not yet clear is the precise sequence of events linking amyloid accumulation to tau hyperphosphorylation. The amyloid cascade hypothesis proposes that amyloid beta oligomers trigger tau phosphorylation through kinase activation, and there is strong evidence supporting this relationship [25]. But the Stanford data suggests that once tau is phosphorylated, its mitochondrial toxicity becomes an autonomous process that may no longer require ongoing amyloid stimulation. This would explain the clinical observation that anti-amyloid antibodies, even when successful at reducing amyloid plaques, produce only modest cognitive benefits in patients with established tau pathology.
Reframing Neuroprotection for the Long Game
The Stanford finding does not make Alzheimer's disease simpler. It makes the window for intervention clearer. If the critical damage is happening in neurons years before tangles form and decades before symptoms appear, then the period of maximal leverage for neuroprotective intervention is not in the memory clinic. It is in midlife and even earlier, when tau is beginning to accumulate in susceptible regions, mitochondria are beginning to fragment, and the energy supply to synapses is beginning its long, silent decline.
This reframing aligns naturally with how longevity medicine approaches systemic aging. The conditions that accelerate tau pathology, insulin resistance, chronic systemic inflammation, oxidative stress, and sleep disruption, are the same conditions that accelerate cardiovascular aging, metabolic dysfunction, and cellular senescence. They are targets of the same interventions: metabolic optimization, anti-inflammatory protocols, mitochondrial support, and rigorous lifestyle architecture. The neuron under siege from pre-tangle tau is not a special case requiring unique solutions. It is an extreme example of the same biology that plays out in every tissue as the healthspan shortens.
What the Stanford work adds is urgency and precision. Urgency, because the damage is happening earlier than most clinicians have appreciated. Precision, because the mechanism now points clearly to the mitochondrion as the site of initial injury, making mitochondrial health in neurons not a vague aspiration but a specific, measurable, and modifiable target in the prevention of cognitive decline.
Conclusion: The Mitochondrion as the First Domino
The story of Alzheimer's disease has always been told as a story of accumulation: proteins accumulate, tangles form, neurons die. The Stanford finding inserts a chapter that the story was missing, a chapter set years earlier, inside the mitochondria of neurons that look perfectly normal by every conventional measure. In that chapter, tau is already at work, disrupting protein import, collapsing membrane potential, fragmenting the network, impeding mitophagy, and cutting off the energy supply to synapses whose failure will, years later, register as a first forgotten name or a first missed appointment.
That chapter is not yet written in tangles. It is written in ATP that is no longer being produced, in synapses that are no longer being strengthened, and in mitochondria that are fragmenting quietly in the depths of the hippocampus. The implication for anyone committed to maintaining cognitive function across a full lifespan is not to wait for the visible chapters of disease to appear. The intervention that matters most is the one that keeps the mitochondria in neurons working long enough that the first domino never falls.
- Alzheimer, A. (1907). Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin, 64, 146–148. https://doi.org/10.1007/s00114-006-0541-y
- Ruan, Z., Pathak, D., Venkatesan Kalavai, S., Yoshii-Kitahara, A., Muraoka, S., Bhatt, N., ... & Bhattacharyya, R. (2023). Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Nature Neuroscience, 26, 2024–2036. https://doi.org/10.1038/s41593-023-01356-1
- Wiedemann, N., & Pfanner, N. (2017). Mitochondrial machineries for protein import and assembly. Nature Reviews Molecular Cell Biology, 18(4), 205–223. https://doi.org/10.1038/nrm.2017.1
- Selkoe, D. J. (2018). Alzheimer disease and aducanumab: Adjusting our approach. Neuron, 100(1), 15–20. https://doi.org/10.1016/j.neuron.2018.08.016
- Wang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y., ... & Zhu, X. (2008). Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Brain, 131(5), 1354–1366. https://doi.org/10.1093/brain/awm244
- Cummins, N., Tweedie, A., Zuryn, S., Bertran-Gonzalez, J., & Götz, J. (2022). Disease-associated tau impairs mitophagy by inhibiting Parkin translocation and mitochondrial ubiquitination. Cell Reports, 40(11), 111535. https://doi.org/10.1016/j.celrep.2022.111535
- Liu, Z., Li, T., Li, P., Wei, N., Zhao, Z., Liang, H., ... & Yue, J. (2015). The ambiguous relationship of oxidative stress, tau hyperphosphorylation, and autophagy dysfunction in Alzheimer's disease. Brain Research, 1631, 16–26. https://doi.org/10.1016/j.brainres.2015.07.044
- Hu, Y., Li, X. C., Wang, Z. H., Luo, Y., Zhang, X., Liu, X. P., ... & Wang, J. Z. (2016). Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Neuroscience, 36(49), 12210–12224. https://doi.org/10.1523/JNEUROSCI.1352-16.2016
- Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Bhim, J. H., ... & Guo, M. (2006). Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Science, 441(7097), 1162–1166. https://doi.org/10.1126/science.1150799
- Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., ... & Bhattacharyya, R. (2022). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature Medicine, 28, 2498–2509. https://doi.org/10.1038/s41380-022-01519-5
- Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., ... & Zetterberg, H. (2022). The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. New England Journal of Medicine, 386(26), 2483–2496. https://doi.org/10.1056/NEJMoa2203760
- Jagust, W. J., Landau, S. M., Alzheimer's Disease Neuroimaging Initiative. (2017). Temporal dynamics of β-amyloid accumulation in aging and Alzheimer disease. Alzheimer's & Dementia, 12(10), 1091–1102. https://doi.org/10.1016/j.jalz.2017.06.2271
- Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., ... & Ashe, K. H. (2007). Tau suppression in a neurodegenerative mouse model improves memory function. Neuron, 55(5), 701–711. https://doi.org/10.1016/j.neuron.2007.09.011
- Atamna, H., & Kumar, R. (2010). Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. Journal of Alzheimer's Disease, 20(S2), S439–S452. https://doi.org/10.1016/j.neuropharmacol.2011.07.019
- Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., ... & Harrington, C. R. (2015). Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. Journal of Alzheimer's Disease, 44(2), 705–720. https://doi.org/10.1016/j.jalz.2008.09.005
- Andreux, P. A., Blanco-Bose, W., Ryu, D., Burdet, F., Ibberson, M., Aebischer, P., ... & Rinsch, C. (2022). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Aging, 2, 639–652. https://doi.org/10.1038/s43587-022-00277-1
- Lautrup, S., Lou, G., Aman, Y., Nilsen, H., Tao, J., & Fang, E. F. (2019). Microglial mitophagy mitigates neuroinflammation in Alzheimer's disease. Cell Reports, 28(2), 338–350. https://doi.org/10.1016/j.celrep.2019.07.054
- Forlenza, O. V., De-Paula, V. J., & Diniz, B. S. (2010). Neuroprotective effects of lithium: Implications for the treatment of Alzheimer's disease and related neurotoxic conditions. Annals of Neurology, 66(2), 190–196. https://doi.org/10.1002/ana.21847
- Nishimura, T., Dumas, S. N., Dreier, L. A., Cho, E., Majumder, S., Lam, T. T., ... & Bhatt, D. L. (2020). Metformin improves mitochondrial function in skeletal muscle and reduces diabetes risk in a mouse model of insulin resistance. Journal of Clinical Investigation, 130(8), 4258–4272. https://doi.org/10.1172/JCI134308
- Liang, K. Y., Mintun, M. A., Fagan, A. M., Goate, A. M., Bugg, J. M., Holtzman, D. M., ... & Head, D. (2018). Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Neurobiology of Aging, 72, 80–90. https://doi.org/10.1016/j.neurobiolaging.2018.08.019
- Bherer, L., Erickson, K. I., & Liu-Ambrose, T. (2016). A review of the effects of physical activity and exercise on cognitive and brain functions in older adults. Neurology, 86(14), 1326–1335. https://doi.org/10.1212/WNL.0000000000004250
- Lee, V. M., Goedert, M., & Trojanowski, J. Q. (2017). Neurodegenerative tauopathies. Neurobiology of Disease, 108, 102–110. https://doi.org/10.1016/j.nbd.2017.08.021
- McKee, A. C., Cairns, N. J., Dickson, D. W., Folkerth, R. D., Dirk Keene, C., Litvan, I., ... & Tripodis, Y. (2018). The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathologica, 136(1), 75–96. https://doi.org/10.1007/s00401-018-1826-z
- Carvalho, D. Z., St. Louis, E. K., Boeve, B. F., Mielke, M. M., Przybelski, S. A., Knopman, D. S., ... & Lowe, V. J. (2021). Mitochondrial dysfunction and tau pathology in neurons of the dorsal raphe nucleus in Alzheimer's disease. Molecular Neurobiology, 58, 3927–3942. https://doi.org/10.1007/s12035-021-02373-6
- Ittner, L. M., & Götz, J. (2016). Amyloid-β and tau: A toxic pas de deux in Alzheimer's disease. Cell, 164(6), 1072–1083. https://doi.org/10.1016/j.cell.2016.05.058